

[Click here to access the guidelines/NICE algorithm](#)

**N&WICS - TA803 - Risankizumab - Psoriatic arthritis after inadequate response to DMARDs**

Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: ☐

If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. ☐

<b>Patient NHS No:</b>	<b>Trust:</b>	<b>Practice Name:</b>
<b>Patient Hospital No:</b> <input type="text"/>	<b>Consultant Making Request:</b> <input type="text"/>	<b>Practice Postcode:</b>
<b>Patient's Initials and DoB:</b>		<b>Practice Code:</b>
<b>Notification Email Address:</b> <input type="text"/> (@NHS.net account ONLY)		<b>Contact name &amp; number:</b> <input type="text"/>
<b>Start date of requested treatment:</b> <input type="text"/>	<b>Provider:</b> <input type="checkbox"/> Private <input type="checkbox"/> NHS <b>Supplier:</b> <input type="checkbox"/> Homecare <input type="checkbox"/> Hospital	<b>Sub-Type:</b> <input type="text"/> N/A <input type="button" value="v"/> (if applicable)

By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR).

For support regarding IFRs, please contact: [norfolkicd@nhs.net](mailto:norfolkicd@nhs.net)

For support regarding the criteria listed below, please contact: [norfolknontariff@nhs.net](mailto:norfolknontariff@nhs.net)

<b>Please indicate whether patient meets the following NICE criteria:</b>	<b>Please tick</b>
1. Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have: <ul style="list-style-type: none"> <li>peripheral arthritis with 3 or more tender joints and 3 or more swollen joints</li> <li>moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)</li> <li>had 2 conventional DMARDs and at least 1 biological DMARD. Risankizumab is recommended only if the company provides it according to the commercial arrangement.</li> </ul>	<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Assess the response to risankizumab from 16 weeks. Stop risankizumab if psoriatic arthritis has not responded adequately using the Psoriatic Arthritis Response Criteria (PsARC; an adequate response is an improvement in at least 2 of the 4 criteria, 1 of which must be joint tenderness or swelling score, with no worsening in any of the 4 criteria). If PsARC response does not support continuing treatment but there is a PASI 75 response, a dermatologist should decide whether continuing treatment is appropriate based on skin response.	<input type="checkbox"/> Yes <input type="checkbox"/> No
3. If risankizumab is one of a range of suitable treatments, including guselkumab, choose the least expensive (taking into account administration costs, dosage, price per dose and commercial arrangements).	<input type="checkbox"/> Yes <input type="checkbox"/> No
4. Take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the PsARC, and make any adjustments needed.	<input type="checkbox"/> Yes <input type="checkbox"/> No
5. Take into account how skin colour could affect the PASI score and make any adjustments needed.	<input type="checkbox"/> Yes <input type="checkbox"/> No
6. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs).	
Please confirm that the choice of drug is considered the most cost-effective treatment for this individual	

patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.	<input type="checkbox"/> Yes <input type="checkbox"/> No
Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of auditing.	
7. The product is being used as described by local commissioning position.	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>I confirm that the patient meets the criteria for treatment</b>	
Name of person completing: <input type="text"/>	Contact Details: <input type="text"/>
Designation of person completing: <input type="text"/>	Date: <input type="text"/>
Trust Authorising Pharmacist	
Name: <input type="text"/>	
Date: <input type="text"/>	